Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report
Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial growth factors have provided the basis for improved outcomes in select patients with unresectable or metastatic hepatocellular carcinoma. However, for patients with resectable disease, surgery alone or an orthotopi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/6/341 |
| _version_ | 1827660976301801472 |
|---|---|
| author | Maen Abdelrahim Abdullah Esmail Godsfavour Umoru Kiersten Westhart Ala Abudayyeh Ashish Saharia Rafik M. Ghobrial |
| author_facet | Maen Abdelrahim Abdullah Esmail Godsfavour Umoru Kiersten Westhart Ala Abudayyeh Ashish Saharia Rafik M. Ghobrial |
| author_sort | Maen Abdelrahim |
| collection | DOAJ |
| description | Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial growth factors have provided the basis for improved outcomes in select patients with unresectable or metastatic hepatocellular carcinoma. However, for patients with resectable disease, surgery alone or an orthotopic liver transplant remains the standard of care. Within the realms of transplant oncology, neoadjuvant systemic therapy is currently being evaluated as a potential strategy to improve outcomes in patients with HCC. Here, we report excellent response with significant downstaging in a safe manner after neoadjuvant treatment with atezolizumab and bevacizumab in a patient diagnosed with poorly differentiated HCC. As a result of the significant response observed with safe outcomes, the patient was listed for orthotopic liver transplant (OLT) evaluation and transplanted successfully. |
| first_indexed | 2024-03-10T00:02:03Z |
| format | Article |
| id | doaj.art-22cd82424e3848c59978206e5cdc5e83 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T00:02:03Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-22cd82424e3848c59978206e5cdc5e832023-11-23T16:14:15ZengMDPI AGCurrent Oncology1198-00521718-77292022-06-012964267427310.3390/curroncol29060341Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case ReportMaen Abdelrahim0Abdullah Esmail1Godsfavour Umoru2Kiersten Westhart3Ala Abudayyeh4Ashish Saharia5Rafik M. Ghobrial6Section of GI Oncology, Department of Medical Oncology, Houston Methodist Neal Cancer Center, Houston, TX 77030, USASection of GI Oncology, Department of Medical Oncology, Houston Methodist Neal Cancer Center, Houston, TX 77030, USADepartment of Pharmacy, Houston Methodist Hospital, Houston, TX 77030, USAHouston Methodist Radiology, Houston Methodist Hospital, Houston, TX 77030, USASection of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Internal Medicine, Weill Cornell Medical College, New York, NY 10021, USADepartment of Internal Medicine, Weill Cornell Medical College, New York, NY 10021, USASystemic combination therapy of immune checkpoint inhibitors and vascular endothelial growth factors have provided the basis for improved outcomes in select patients with unresectable or metastatic hepatocellular carcinoma. However, for patients with resectable disease, surgery alone or an orthotopic liver transplant remains the standard of care. Within the realms of transplant oncology, neoadjuvant systemic therapy is currently being evaluated as a potential strategy to improve outcomes in patients with HCC. Here, we report excellent response with significant downstaging in a safe manner after neoadjuvant treatment with atezolizumab and bevacizumab in a patient diagnosed with poorly differentiated HCC. As a result of the significant response observed with safe outcomes, the patient was listed for orthotopic liver transplant (OLT) evaluation and transplanted successfully.https://www.mdpi.com/1718-7729/29/6/341transplant oncologyliver transplantationhepatocellular carcinomaimmunotherapyimmune checkpoint inhibitorsCTLA-4 inhibitors |
| spellingShingle | Maen Abdelrahim Abdullah Esmail Godsfavour Umoru Kiersten Westhart Ala Abudayyeh Ashish Saharia Rafik M. Ghobrial Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report Current Oncology transplant oncology liver transplantation hepatocellular carcinoma immunotherapy immune checkpoint inhibitors CTLA-4 inhibitors |
| title | Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report |
| title_full | Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report |
| title_fullStr | Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report |
| title_full_unstemmed | Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report |
| title_short | Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report |
| title_sort | immunotherapy as a neoadjuvant therapy for a patient with hepatocellular carcinoma in the pretransplant setting a case report |
| topic | transplant oncology liver transplantation hepatocellular carcinoma immunotherapy immune checkpoint inhibitors CTLA-4 inhibitors |
| url | https://www.mdpi.com/1718-7729/29/6/341 |
| work_keys_str_mv | AT maenabdelrahim immunotherapyasaneoadjuvanttherapyforapatientwithhepatocellularcarcinomainthepretransplantsettingacasereport AT abdullahesmail immunotherapyasaneoadjuvanttherapyforapatientwithhepatocellularcarcinomainthepretransplantsettingacasereport AT godsfavourumoru immunotherapyasaneoadjuvanttherapyforapatientwithhepatocellularcarcinomainthepretransplantsettingacasereport AT kierstenwesthart immunotherapyasaneoadjuvanttherapyforapatientwithhepatocellularcarcinomainthepretransplantsettingacasereport AT alaabudayyeh immunotherapyasaneoadjuvanttherapyforapatientwithhepatocellularcarcinomainthepretransplantsettingacasereport AT ashishsaharia immunotherapyasaneoadjuvanttherapyforapatientwithhepatocellularcarcinomainthepretransplantsettingacasereport AT rafikmghobrial immunotherapyasaneoadjuvanttherapyforapatientwithhepatocellularcarcinomainthepretransplantsettingacasereport |